SEC Form 4 · accession 0001209191-18-058384
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Vaughn
Officer — Chief Commercial Officer
Period of report
Nov 8, 2018
Accepted (ET)
Nov 13, 2018 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 8, 2018 | M | 3,000 | $31.12 | A | 20,542 | D | |
| Common StockF2,F3,F4,F1 | Nov 8, 2018 | S | 1,100 | $83.9391 | D | 19,442 | D | |
| Common StockF2,F3,F5,F1 | Nov 8, 2018 | S | 1,300 | $85.1846 | D | 18,142 | D | |
| Common StockF2,F3,F6,F1 | Nov 8, 2018 | S | 300 | $85.84 | D | 17,842 | D | |
| Common StockF2,F3,F7,F1 | Nov 8, 2018 | S | 300 | $89.0667 | D | 17,542 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) HoldingF8 | $31.12 | Nov 8, 2018 | M | 3,000 | D | — | Feb 13, 2025 | Common Stock | 3,000 | 36,772 | D |
Explanation of responses
- F1Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $83.66 to $84.20.
- F5Represents weighted average sale price. Actual sale prices ranged from $84.66 to $85.64.
- F6Represents weighted average sale price. Actual sale prices ranged from $85.77 to $85.90.
- F7Represents weighted average sale price. Actual sale prices ranged from $88.88 to $89.42.
- F8The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.